{"id":"W3120723698","doi":"10.1016/j.esmoop.2020.100019","title":"Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","year":2021,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eisai Canada; European Society for Medical Oncology; Eisai; Eli Lilly and Company; Takeda Pharmaceutical Company; Roche; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; AstraZeneca","keywords":"Eribulin; Gemcitabine; Medicine; Internal medicine; Metastatic breast cancer; Triple-negative breast cancer; Oncology; Neutropenia; Regimen; Clinical endpoint; Phases of clinical research; Febrile neutropenia; Breast cancer; Adverse effect; Clinical trial; Cancer; Toxicity","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003993402,0.0002029101,0.0008976417,0.00004511128,0.00008999659,0.00000742168,0.0001705376,0.00004379705,0.0001364663],"category_scores_gemma":[0.0001200693,0.00009120864,0.00008351333,0.0003786728,0.000240309,0.00006455778,0.00007576434,0.0001022274,1.516317e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001154402,"about_ca_system_score_gemma":0.0006000674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008366315,"about_ca_topic_score_gemma":0.005685905,"domain_scores_codex":[0.99792,0.0004159339,0.0008749276,0.0003772757,0.0002504284,0.0001614075],"domain_scores_gemma":[0.9973403,0.001235862,0.0006856517,0.0003116292,0.0003616833,0.00006483535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7705467,0.09939826,0.05958069,0.00005902686,0.001776088,0.00002601462,0.002652188,0.0001542458,0.00006676431,0.000006180212,0.0001606992,0.06557314],"study_design_scores_gemma":[0.5228265,0.1742672,0.2968521,0.0001271324,0.001977581,0.000002118247,0.0007624151,0.0001038334,0.002530336,0.000008571688,0.0004527602,0.0000893941],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863081,0.0001067699,0.000004918503,0.001321652,0.0002026817,0.01116791,0.0008158285,0.000003573507,0.00006855666],"genre_scores_gemma":[0.9972127,0.0004537283,0.000212451,0.0001386519,0.00002783886,0.001380598,0.00008318239,0.00001815967,0.000472653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2477202,"threshold_uncertainty_score":0.371938,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08808522107393496,"score_gpt":0.4514207987133853,"score_spread":0.3633355776394503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}